论文部分内容阅读
目的对阿托伐他汀治疗慢性硬膜下血肿的临床价值进行研究。方法 70例慢性硬膜下血肿患者随机分为对照组和观察组。对照组患者在常规治疗的基础上,使用钻孔引流术进行手术治疗;观察组患者在常规治疗的基础上使用阿托伐他汀治疗。对患者进行随访,观察对照组和观察组患者治疗后的临床效果、日常生活自理能力Barthel指数评分(ADL-BI评分)以及并发症发生的情况。结果经过治疗,观察组患者总有效率(91.43%)与对照组(94.29%)不具有可比性(P>0.05);在ADL-BI评分方面,治疗前两组相差不大(P>0.05),治疗后均有提高,且观察组的ADL-BI评分(66.75±5.18)要比对照组高,P<0.05;在并发症发生的概率上,观察组(8.57%)明显比对照组低(34.29%),P<0.05。结论使用阿托伐他汀治疗慢性硬膜下血肿,效果显著、安全性高、并发症少,能够有效地提高患者生存质量,值得临床上进一步推广使用。
Objective To study the clinical value of atorvastatin in the treatment of chronic subdural hematoma. Methods Seventy patients with chronic subdural hematoma were randomly divided into control group and observation group. The patients in the control group were treated by drilling drainage on the basis of routine treatment. The patients in observation group were treated with atorvastatin on the basis of routine treatment. The patients were followed up to observe the clinical effect of the control group and the observation group after treatment, Barthel Index (ADL-BI score) of daily living ability and the occurrence of complications. Results After treatment, the total effective rate (91.43%) in the observation group was not comparable with that in the control group (94.29%) (P> 0.05). There was no significant difference in the ADL-BI score between the two groups before treatment , Respectively. The ADL-BI scores in the observation group (66.75 ± 5.18) were higher than those in the control group (P <0.05). The probability of complications was significantly lower in the observation group (8.57%) than that in the control group 34.29%), P <0.05. Conclusion Atorvastatin treatment of chronic subdural hematoma, significant effect, high safety, fewer complications, can effectively improve the quality of life of patients, it is worth further promotion of clinical use.